Redeye comments on Isofol’s new update from the ongoing phase Ib/II study with arfolitixorin. Ten patients have now been treated, and no dose-limiting toxicities have been observed, including at the highest dose level of 500 mg/m². Disease control has been achieved in all evaluated patients, and five of the ten have been referred for potentially curative tumor resection. We view the update as confirmation that the encouraging signals from the first interim readout in February are holding up as more patients are added. Alongside the data, Isofol is expanding the planned phase II part to 15–20 sites across four European countries.
LÄS MER
